Presepsin is a novel highly effective sepsis marker (Review)

  • S. D. Shapoval Sepsis Institute of State Institution «Zaporizhia Medical Academy of post-graduate education Ministry of Health of Ukraine»
  • I. L. Savon Sepsis Institute of State Institution «Zaporizhia Medical Academy of post-graduate education Ministry of Health of Ukraine»
  • L. V. Vasylevska Sepsis Institute of State Institution «Zaporizhia Medical Academy of post-graduate education Ministry of Health of Ukraine»
  • M. M. Sofilkanych Sepsis Institute of State Institution «Zaporizhia Medical Academy of post-graduate education Ministry of Health of Ukraine»


In this review the most effective markers of septic process like Procalcitonin, C-reactive protein, and cytokines compared to the new marker – Presepsin (PSP) are analyzed.

At sepsis initiation, PSP increases 30 to 60 minutes after the onset of systemic infection. PSP levels at admission to the hospital predict the risk of adverse and adverse effects that other markers used for the diagnosis of sepsis do not have.


Marazzi MG, Randelli F, Brioschi M et al. Presepsin: A potential biomarker of PJI? A comparative analysis withknown and new infection biomarkers. Int J Immunopathol Pharmacol. 2018; 31: 394632017749356. DOI: 10.1177/0394632017749356.

Sparacino M, Russo E, Vitali S et al. Plasma concentration of presepsin and its relationship to the diagnosis of infections in multiple trauma patients admitted to intensive care. Microbiologia Medica 2017; 32 (2). DOI: 10.4081/mm.2017.6870.

Bomberg H, Klingele M, Wagenpfeil S et al., Presepsin (sCD14-ST) Is a Novel Marker for Risk Stratification in Cardiac Surgery Patients. Anesthesiology 2017; 126 (4): 631–642. DOI: 10.1097/ALN.0000000000001522.

Tanır Basaranoglu S, Karadag-Oncel E, Aykac K et al., Presepsin: A new marker of catheter related blood stream infections in pediatric patients, J Infect Chemother. 2017; 24 (1): 25–30. DOI: 10.1016/j.jiac.2017.08.012 28.

Chenevier-Gobeaux C, ,Bardet V, Poupet H et al. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Clin Chim Acta, 2016, 74 (1): 93–97. DOI: 10.1684/abc.2015.1112.

Matera G, Quirino A, Peronace C et al. Soluble CD14 subtype, a new biomarker in predicting outcome of critically ill septic patients: an observational prospective study. Am J Med Sci. 2017; 353 (6): 543–551. DOI: 10.1016/j.amjms.2017.03.036.

Arai Y, Mizugishi K, Nonomura K et al. Phagocytosis by human monocytes is required for the secretion of Presepsin. J Infect Chemother. 2015; 21 (8):564–569. DOI: 10.1016/j.jiac.2015.04.011.

Nakamura Y, Murai A, Mizunuma M et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or withoutacute kidney injury. J Infect Chemother. 2015; 21 (4): 257–263. DOI: 10.1016/j.jiac.2014.12.001.

Godin M, Murrau P, Mehta RL. Clinical Approach to the Patient with AKI and Sepsis. Semin Nephrol. 2015; 35 (1): 12–22. DOI: 10.1016/j.semnephrol.2015.01.003.

Koakutsu T, Sato T, Aizawa T et al. Postoperative changes in presepsin level and values predictive of surgical site infection after spinal surgery: A single center, prospective observational study. Spine (Phila Pa 1976). 2018; 43 (8): 578–584. DOI: 10.1097/BRS.0000000000002376.

Klouche K, Cristol JP, Devin J et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and communityacquired pneumonia in ICU patients. Ann. Intensive Care. 2016; 6: 59. DOI: 10.1186/s13613-016-0160-6.

Qi ZJ, Yu H, Zhang J. Presepsin as a novel diagnostic biomarker for differentiating active pulmonary tuberculosis from bacterial community acquired pneumonia. Clin Chim Acta. 2017; 478: 152–156. DOI: 10.1016/j.cca.2017.12.045.

Liu Y, Hou JH, Li Q et al. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis.Springerplus. 2016; 5 (1): 2091. DOI: 10.1186/s40064-016-3591-5.

Suzuki H, Watanabe М, Nakamura N et al. Evidence That Presepsin is an Early Marker of Postoperative Infection After Cardiac Surgery. Yamagata University Hospital, Yamagata-shi, Japan, 2015.

Sargentini V, Ceccarelli G, D'Alessandro M et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clin Chem Lab Med. 2015; 53 (4): 567–573. DOI: 10.1515/cclm-2014-0119.

Song X, Song Y, Yuan Y, Zhang P, Zhang X. Prognostic value of presepsin for outcomes and complications in enterocutaneous fistula complicated by abdominal sepsis.Int J Surg. 2016; Pt A: 96–101. DOI: 10.1016/j.ijsu.2016.07.070.

Yu H, Qi Z, Hang C et al. Evaluating the value of dynamic procalcitonin and presepsin measurement for patients with severe sepsis. Am J Emerg Med. 2017; 35 (6): 835–841. DOI: 10.1016/j.ajem.2017.01.037.

Nagata T, Yasuda Y, Ando M et al. Clinical Impact of Kidney Function on Presepsin Levels PLoS One. 2015; 10 (6): e0129159. DOI: 10.1371/journal.pone.0129159.

Nakamura Y, Hoshino K, Kiyomi F., Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury. Clin Chim Acta. 2018; 490: 200–206. DOI: 10.1016/j.cca.2018.09.013.

Koch C, Ruhrmann S, Pöhlmann M et al. Longitudinal Evaluation of Plasma Concentrations of Presepsin in Patients after Severe Trauma: A Prospective Observational Study. Surg Infect (Larchmt). 2018; 19 (5): 480–487. DOI: 10.1089/sur.2017.266.

Koizumi Y, Shimizu K, Shigeta M et al. Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients. BMC Infect Dis. 2017; 17 (1): 27. DOI: 10.1186/s12879-016-2116-8.

Koh H, Aimoto M, Katayama T et al. Diagnostic value of levels of presepsin (soluble CD14-subtype) in febrile neutropenia in patients with hematological disorders. J Infect Chemother. 2016; 22 (7): 466–471. DOI: 10.1016/j.jiac.2016.04.002.

Shiota J, Tagawa H, Ohura N, Kasahara H. Presepsin is a potent biomarker for diagnosing skin wound infection in hemodialysis patients Compared to white blood cell count, highsensitivity C-reactive protein, procalcitonin, and soluble CD14. Renal Replacement Therapy. 2017; 3. DOI: 10.1186/s41100-017-0113.

Cikot M, Kasapoglu P, Isiksacan N et al. The importance of presepsin value in detection of gastrointestinal anastomotic leak: a pilot study. J Surg Res. 2018; 228: 100–106. DOI: 10.1016/j.jss.2018.02.059.

Savić D, Simović A, Marković S et al. The Role of Presepsin Obtained from Tracheal Aspirates in the Diagnosis of Early Onset Pneumonia in Intubated Newborns.I ndian J Pediatr. 2018; 85 (11): 968–973. DOI: 10.1007/s12098-018-2676-2.

Takahashi G, Shibata S, Fukui Y, Okamura Y, Inoue Y. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury. Diagn Microbiol Infect Dis. 2016; 86 (2): 205–210. DOI: 10.1016/j.diagmicrobio.2016.07.015.

Shiota J, Ohura N, Higashikawa S et al. Presepsin as a predictor of critical colonization in CLI hemodialysis patients. Wound Repair Regen. 2015; 24 (1): 189–194. DOI: 10.1111/wrr.12371.

Watanabe N, Shii Т, Kita N et al. Diagnostic Value of Presepsin, C-Reactive Protein, and Procalcitonon in Pleural Effusion. Am J Resplr Crit Gare Med. 2018; 197: 176. DOI: 10.1186/s12890-018-0740-3.

How to Cite
Shapoval, S. D., Savon, I. L., Vasylevska, L. V., & Sofilkanych, M. M. (2020). Presepsin is a novel highly effective sepsis marker (Review). Modern Medical Technology, (1(44), 84-87.
Reviews of literature, lections